12/17
04:35 pm
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
LB Pharmaceuticals (NASDAQ:LBRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
12/11
04:20 pm
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
LB Pharmaceuticals (NASDAQ:LBRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
12/11
08:44 am
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) had its price target raised by analysts at Stifel Nicolaus from $27.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
LB Pharmaceuticals (NASDAQ:LBRX) had its price target raised by analysts at Stifel Nicolaus from $27.00 to $35.00. They now have a "buy" rating on the stock.
12/10
06:01 pm
lbrx
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/10
05:04 pm
lbrx
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
12/9
07:04 pm
lbrx
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices [Yahoo! Finance]
Low
Report
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices [Yahoo! Finance]
12/9
08:00 am
lbrx
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
Low
Report
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
12/5
04:23 pm
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
High
Report
LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
11/24
08:00 am
lbrx
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference
11/12
04:53 pm
lbrx
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
11/12
04:15 pm
lbrx
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
11/12
08:48 am
lbrx
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer [Yahoo! Finance]
Medium
Report
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer [Yahoo! Finance]
11/12
08:00 am
lbrx
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer
Medium
Report
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer
11/6
04:05 pm
lbrx
LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference
Low
Report
LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference
11/6
08:00 am
lbrx
LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates
Medium
Report
LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates
10/14
08:39 am
lbrx
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs [Yahoo! Finance]
Low
Report
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs [Yahoo! Finance]
10/14
08:30 am
lbrx
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
Low
Report
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
10/9
07:15 am
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) was upgraded by analysts at Zacks Research to a "hold" rating.
Medium
Report
LB Pharmaceuticals (NASDAQ:LBRX) was upgraded by analysts at Zacks Research to a "hold" rating.
10/7
07:53 am
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
LB Pharmaceuticals (NASDAQ:LBRX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
10/6
08:30 am
lbrx
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms
Low
Report
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms
10/6
08:08 am
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $34.00 price target on the stock.
Low
Report
LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $34.00 price target on the stock.
10/6
07:20 am
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Low
Report
LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
10/6
07:01 am
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) was given a new $27.00 price target on by analysts at Stifel Nicolaus.
Low
Report
LB Pharmaceuticals (NASDAQ:LBRX) was given a new $27.00 price target on by analysts at Stifel Nicolaus.